Amalyte Pharmaceuticals, LLC has entered into a worldwide collaboration with Meiji Seika Kaisha Ltd. (MSK), to discover, develop, and commercialize a lead compound, ME3301 (AM3301), and a class of dual-acting anti-inflammatory compounds for a variety of human health applications.
Amalyte is a US-based biopharmaceutical company focused on immune and inflammatory diseases, while MSK is a Japan-based manufacturer and marketer of food, pharmaceutical, and healthcare products.
Under the terms of the agreement, Amalyte would have exclusive rights to develop and commercialize the resulting products worldwide, except in Japan and several Asian countries where MSK has a development and commercialization option for all products arising from the collaboration. Amalyte and MSK would co-market collaboration products in Spain and Portugal.
Amalyte intends to develop AM3301 for multiple clinical indications in gastrointestinal inflammatory (Inflammatory bowel disease and irritable bowel syndrome) and in allergic (rhinitis and asthma) diseases.
As per the agreement, MSK would receive up-front and milestone payments as well as royalties upon commercialization from Amalyte.
No comments:
Post a Comment